Bifidobacterial ß-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments
Autor: | Valentina Ambrogi, Francesca Bottacini, John Mac Sharry, Justin van Breen, Ellen O’Keeffe, Dan Walsh, Barry Schoemaker, Linqiu Cao, Bas Kuipers, Cordula Lindner, Maria Luisa Jimeno, Elisa G. Doyagüez, Oswaldo Hernandez-Hernandez, F. Javier Moreno, Margriet Schoterman, Douwe van Sinderen |
---|---|
Přispěvatelé: | Ministerio de Economía y Competitividad (España), Irish Government, European Commission |
Rok vydání: | 2021 |
Předmět: |
Microbiology (medical)
medicine.medical_treatment Disaccharide Oligosaccharides Gut microbiota medicine.disease_cause Microbiology chemistry.chemical_compound medicine Trisaccharide Lactose Escherichia coli Original Research Bifidobacterium chemistry.chemical_classification biology Prebiotic Infant biology.organism_classification QR1-502 In vitro Enzyme Prebiotics chemistry Biochemistry Bifidogenic Microbiome |
Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname Frontiers in microbiology Frontiers in Microbiology Frontiers in Microbiology, Vol 12 (2021) |
Popis: | In the current study the ability of four previously characterized bifidobacterial β-galactosidases (designated here as BgaA, BgaC, BgaD, and BgaE) to produce galacto-oligosaccharides (GOS) was optimized. Of these enzymes, BgaA and BgaE were found to be promising candidates for GOS production (and the corresponding GOS mixtures were called GOS-A and GOS-E, respectively) with a GOS concentration of 19.0 and 40.3% (of the initial lactose), respectively. GOS-A and GOS-E were partially purified and structurally characterized. NMR analysis revealed that the predominant (non-lactose) disaccharide was allo-lactose in both purified GOS preparations. The predominant trisaccharide in GOS-A and GOS-E was shown to be 3′-galactosyllactose, with lower levels of 6′-galactosyllactose and 4′-galactosyllactose. These three oligosaccharides have also been reported to occur in human milk. Purified GOS-A and GOS-E were shown to be able to support bifidobacterial growth similar to a commercially available GOS. In addition, GOS-E and the commercially available GOS were shown to be capable of reducing Escherichia coli adhesion to a C2BBe1 cell line. Both in vitro bifidogenic activity and reduced E. coli adhesion support the prebiotic potential of GOS-E and GOS-A. |
Databáze: | OpenAIRE |
Externí odkaz: |